The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine.
The pathogenesis of carcinogenic human papillomavirus (HPV) infections of the cervix includes early induction of peripheral tolerance of tissue-infiltrating lymphocytes and an imbalanced Th2 response to HPV early virus proteins. As lesions become progressively dysplastic, major histocompatibility complex (MHC)-1 molecules are down-regulated on the surface of abnormal keratinocytes. When the target of MHC-1 class-restricted cytotoxic lymphocytes disappears, immune deviation to a Th2 response becomes more dominant. After severely dysplastic lesions become invasive, cervical cancer cells die and release HPV E6 and E7 oncoproteins that react with anti-E6 and anti-E7 antibodies to form insoluble immune complexes in antibody excess under the continuing influence of immune deviation. On the basis of this knowledge of the pathogenesis of advanced cervical cancer, we believe that successful immunotherapeutic treatments of these patients will use a vaccine formulation that will break peripheral tolerance in association with biological response modifiers that will enable the patient's immune system to switch classes from Th2 to Th1 while up-regulating MHC-1 molecules on cancer cells. Like prophylactic vaccines against HPV, successful therapeutic vaccine against cervical cancer may have to be universal rather than individualized to be efficacious.
Ghim
S J
SJ
Cervical Cancer Research Institute, The Western Pennsylvania Hospital Foundation, 720 Gross Street, Pittsburgh, Pennsylvania 15224, USA.
Sundberg
J
J
Delgado
G
G
Jenson
A B
AB
D015195:Drug Design; D005260:Female; D006239:Haplotypes; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000096:biosynthesis; D018418:Th2 Cells / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D014765:Viral Vaccines / Q000096:biosynthesis / Q000627:therapeutic use*
D015395:Histocompatibility Antigens Class I; D009856:Oncogene Proteins, Viral; D011994:Recombinant Proteins; D014765:Viral Vaccines